Measure for measure: Minimal residual disease in CLL

Abstract

In this issue of Blood, Kwok and colleagues have provided a wealth of retrospective clinical data that greatly expands our appreciation for the prognostic importance of flow-cytometric residual disease measurement across a spectrum of clinical presentations in chronic lymphocytic leukemia (CLL).1